Hudson Capital Management LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Hudson Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 11.9% during the second quarter, owning 6,105 shares worth approximately $3.2 million.
• Several hedge funds have also modified their holdings in Regeneron, including Nuveen LLC's new position valued at approximately $343.76 million, contributing to hedge funds owning 83.31% of the stock.
• Regeneron reported a strong quarterly earnings result with an EPS of $12.89, significantly exceeding estimates, and declared a quarterly dividend of $0.88 per share.

Hudson Capital Management LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,105 shares of the biopharmaceutical company's stock after purchasing an additional 647 shares during the period. Hudson Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $3,205,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of REGN. Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $343,764,000. Pacer Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after acquiring an additional 390,374 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after acquiring an additional 174,056 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after acquiring an additional 121,545 shares during the last quarter. Finally, Retirement Systems of Alabama grew its position in shares of Regeneron Pharmaceuticals by 476.4% during the first quarter. Retirement Systems of Alabama now owns 131,382 shares of the biopharmaceutical company's stock worth $83,326,000 after acquiring an additional 108,589 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a "buy" rating in a research report on Monday. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target for the company. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target for the company. in a report on Friday, August 1st. Finally, Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $817.88.

Regeneron Pharmaceuticals Trading Down 1.2%

NASDAQ:REGN opened at $557.73 on Tuesday. The company has a market capitalization of $59.11 billion, a PE ratio of 14.06, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The stock has a fifty day simple moving average of $573.67 and a 200-day simple moving average of $563.46.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.56 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.